TD Cowen Begins Coverage on Rapport Therapeutics (NASDAQ:RAPP)

TD Cowen assumed coverage on shares of Rapport Therapeutics (NASDAQ:RAPP) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating on the stock.

RAPP has been the topic of a number of other research reports. Jefferies Financial Group started coverage on Rapport Therapeutics in a research report on Tuesday. They set a buy rating and a $35.00 target price on the stock. Stifel Nicolaus started coverage on Rapport Therapeutics in a research report on Tuesday. They set a buy rating and a $35.00 target price on the stock.

Rapport Therapeutics Stock Down 6.8 %

Rapport Therapeutics stock opened at $23.30 on Tuesday. Rapport Therapeutics has a 1-year low of $18.00 and a 1-year high of $27.11.

Insider Activity at Rapport Therapeutics

In related news, Director James Healy purchased 44,032 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were purchased at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the transaction, the director now directly owns 40,851 shares of the company’s stock, valued at approximately $1,001,666.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.